Soonmyung Paik

Summary

Affiliation: National Surgical Adjuvant Breast and Bowel Project
Country: USA

Publications

  1. ncbi request reprint Molecular assays to predict prognosis of breast cancer
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    Clin Adv Hematol Oncol 5:681-2. 2007
  2. ncbi request reprint Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project Foundation, Four Allegheny Center 5th Floor, East Commons Professional Building, Pittsburgh, PA 15212, USA
    Clin Cancer Res 12:1019s-1023s. 2006
  3. ncbi request reprint HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
    S Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Allegheny General Hospital, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 92:1991-8. 2000
  4. ncbi request reprint Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Nat Clin Pract Oncol 2:246-54. 2005
  5. ncbi request reprint Molecular profiling of breast cancer
    Soonmyung Paik
    Division of Disease, NSABP Foundation, Pittsburgh, Pennsylvania 15212, USA
    Curr Opin Obstet Gynecol 18:59-63. 2006
  6. ncbi request reprint Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
  7. doi request reprint Is gene array testing to be considered routine now?
    Soonmyung Paik
    NSAB Foundation, Pittsburgh, USA, and Samsung Cancer Research Institute, Seoul, South Korea
    Breast 20:S87-91. 2011
  8. ncbi request reprint Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania 15206, USA
    Oncologist 12:631-5. 2007
  9. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
  10. ncbi request reprint A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004

Detail Information

Publications50

  1. ncbi request reprint Molecular assays to predict prognosis of breast cancer
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    Clin Adv Hematol Oncol 5:681-2. 2007
  2. ncbi request reprint Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project Foundation, Four Allegheny Center 5th Floor, East Commons Professional Building, Pittsburgh, PA 15212, USA
    Clin Cancer Res 12:1019s-1023s. 2006
    ..Recent developments in gene expression profiling technologies are discussed with their implications in clinical management of endocrine receptor-positive breast cancer...
  3. ncbi request reprint HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
    S Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Allegheny General Hospital, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 92:1991-8. 2000
    ..We hypothesized that AC would be superior to CMF only in the HER2-positive patients...
  4. ncbi request reprint Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Nat Clin Pract Oncol 2:246-54. 2005
    ..For older samples, real-time reverse transcription-polymerase chain reaction is the method of choice for gene-expression profiling...
  5. ncbi request reprint Molecular profiling of breast cancer
    Soonmyung Paik
    Division of Disease, NSABP Foundation, Pittsburgh, Pennsylvania 15212, USA
    Curr Opin Obstet Gynecol 18:59-63. 2006
    ..This review is a comprehensive survey of molecular-profiling literature published since 2004...
  6. ncbi request reprint Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
    ..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide...
  7. doi request reprint Is gene array testing to be considered routine now?
    Soonmyung Paik
    NSAB Foundation, Pittsburgh, USA, and Samsung Cancer Research Institute, Seoul, South Korea
    Breast 20:S87-91. 2011
    ..Evidence for their clinical utility was reviewed to determine whether any of them should be considered as routine clinical test...
  8. ncbi request reprint Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania 15206, USA
    Oncologist 12:631-5. 2007
    ..A prospective study-the Trial Assigning Individualized Options for Treatment (Rx) (TAILORx)-to examine whether chemotherapy is required for the intermediate-risk group defined by the RS is accruing in North America...
  9. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  10. ncbi request reprint A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  11. pmc Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh, Pittsburgh, PA 15212, USA
    J Clin Oncol 28:3937-44. 2010
    ....
  12. doi request reprint Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  13. doi request reprint Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Gong Tang
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
    Breast Cancer Res Treat 127:133-42. 2011
    ..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit...
  14. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  15. pmc Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
    D Craig Allred
    National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
    J Clin Oncol 30:1268-73. 2012
    ..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen...
  16. pmc Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
    Katherine L Pogue-Geile
    Affiliations of authors National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA J HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG, Jr, JPC, NW, SP Division of Pathology, NSABP KLP G, CK, NT, PGG, DF, YT, OLB, AL, S IK, MLR, MYR, NLB, S RK, ZDH Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA J HJ, HB, JPC PhenoPath Laboratories, PLLC, Seattle, Germany
    J Natl Cancer Inst 105:1782-8. 2013
    ..This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31...
  17. pmc Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
    Sandra M Swain
    Sandra M Swain, Gong Tang, Charles E Geyer Jr, Priya Rastogi, James N Atkins, Paul P Donnellan, Louis Fehrenbacher, Catherine A Azar, André Robidoux, Jonathan A Polikoff, Adam M Brufsky, David D Biggs, Edward A Levine, John L Zapas, Louise Provencher, Soonmyung Paik, Joseph P Costantino, Eleftherios P Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project NSABP Norman Wolmark, Allegheny General Hospital, Allegheny Health Network Gong Tang and Joseph P Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health Priya Rastogi, University of Pittsburgh Cancer Institute Adam M Brufsky, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA Sandra M Swain, Medstar Washington Hospital Center, Washington, DC Charles E Geyer Jr, Virginia Commonwealth University, Richmond, VA James N Atkins, UCLA-SFVP Department of Medicine
    J Clin Oncol 31:3197-204. 2013
    ....
  18. pmc Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
    Chungyeul Kim
    National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
    J Clin Oncol 29:4160-7. 2011
    ..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors...
  19. doi request reprint Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value
    Patrick G Gavin
    National Surgical Adjuvant Breast and Bowel Project, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15212, USA
    Clin Cancer Res 18:6531-41. 2012
    ..The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer...
  20. pmc Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08
    Kay Pogue-Geile
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 105:989-92. 2013
    ....
  21. ncbi request reprint Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  22. ncbi request reprint Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay
    Seok Jin Kim
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul, 135 710, South Korea
    Ann Hematol 93:437-47. 2014
    ....
  23. ncbi request reprint Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
    ..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)...
  24. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
    ....
  25. ncbi request reprint erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
    S Paik
    National Surgical Adjuvant Breast and Bowel Project, Department of Human Oncology, Allegheny University of Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1361-70. 1998
    ..Overexpression of the erbB-2 protein by breast cancer cells has been suggested to be a predictor of response to doxorubicin. A retrospective study was designed to test this hypothesis...
  26. ncbi request reprint Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
    ..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)...
  27. ncbi request reprint Gene-expression-based prognostic assays for breast cancer
    Chungyeul Kim
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Nat Rev Clin Oncol 7:340-7. 2010
    ....
  28. ncbi request reprint Clinical trial methods to discover and validate predictive markers for treatment response in cancer
    Soonmyung Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
    Biotechnol Annu Rev 9:259-67. 2003
    ..In this paper, design strategies for clinical trials aimed at disclosing predictive markers are discussed...
  29. pmc Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists
    Chungyeul Kim
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, Pennsylvania, USA
    Arch Pathol Lab Med 133:855-9. 2009
    ..Gene expression-based prognostic assays for breast cancer are now available as commercial reference laboratory tests covered by insurance...
  30. doi request reprint Genomics of adjuvant therapy for breast cancer
    Seong Rim Kim
    Division of Pathology, National Surgical Breast and Bowel Project Foundation, Pittsburgh, PA, USA
    Cancer J 17:500-4. 2011
    ..Postneoadjuvant setting can be then used for patients with gross residual disease to test novel therapeutic agents...
  31. pmc A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes
    Debora Fumagalli
    Department of Pathology, National Surgical Adjuvant Breast and Bowel Project, 1307 Federal St, Pittsburgh, PA 15212, USA
    BMC Cancer 10:101. 2010
    ..Our goal was to develop a high throughput, cost-effective and simple methodology for the detection of clinically relevant hot spot mutations in colon cancer...
  32. ncbi request reprint Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy
    James Dignam
    Department of Biostatistics, University of Chicago, IL, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Methods Mol Biol 184:169-89. 2002
  33. ncbi request reprint HER-2 and choice of adjuvant chemotherapy in breast cancer
    S Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Semin Oncol 28:332-5. 2001
    ..This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy...
  34. ncbi request reprint Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
    ..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women...
  35. ncbi request reprint Gene expression profiling of breast cancer: a new tumor marker
    Laura J Van't Veer
    Breast Oncology Program, University of Michigan Health System, 1500 E Medical Center Dr, CCGC 6203, Ann Arbor, MI 48109 0942, USA
    J Clin Oncol 23:1631-5. 2005
  36. ncbi request reprint Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer
    Nicole J McCarthy
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 8:3857-62. 2002
    ....
  37. ncbi request reprint Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement
    Steven E Come
    Breast Cancer Program, Beth Israel Deaconess Medical Center Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 12:997s-1000s. 2006
  38. ncbi request reprint Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization
    Ralf T Henke
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Methods 38:253-62. 2006
    ..We conclude that ISH is a reliable and cost effective approach to gene expression analysis in archival tissues that is amenable to screening of series of tissues or of genes of interest...
  39. ncbi request reprint HER2 testing in breast cancer: NCCN Task Force report and recommendations
    Robert W Carlson
    Stanford Hospital and Clinics
    J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006
    ..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed...
  40. ncbi request reprint NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 7:416-21. 2006
  41. ncbi request reprint Anthracyclines in the treatment of HER2-negative breast cancer
    Soonmyung Paik
    J Natl Cancer Inst 100:2-4. 2008
  42. doi request reprint Development of the 21-gene assay and its application in clinical practice and clinical trials
    Joseph A Sparano
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Clin Oncol 26:721-8. 2008
    ....
  43. ncbi request reprint New generation of molecular prognostic and predictive tests for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Semin Oncol 34:S10-6. 2007
    ....
  44. doi request reprint Research issues affecting preoperative systemic therapy for operable breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
    J Clin Oncol 26:806-13. 2008
    ..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care...
  45. doi request reprint HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Soonmyung Paik
    N Engl J Med 358:1409-11. 2008
  46. doi request reprint Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    John T Hamm
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
    Clin Breast Cancer 8:257-63. 2008
    ..This trial also evaluated the feasibility of tissue collection for gene-expression profiling...
  47. ncbi request reprint An ideal prognostic test for estrogen receptor-positive breast cancer?
    Soonmyung Paik
    J Clin Oncol 26:4058-9. 2008
  48. ncbi request reprint American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  49. ncbi request reprint Predictive value of microsatellite instability-high remains controversial
    George P Kim
    J Clin Oncol 25:4857; author reply 4857-8. 2007
  50. ncbi request reprint Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
    George P Kim
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 25:767-72. 2007
    ..The role of high-degree microsatellite instability (MSI-H) as a marker to predict benefit from adjuvant chemotherapy remains unclear...